These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 33000474)

  • 21. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.
    Ren S; Huang S; Ye X; Feng L; Lu Y; Zhou C; Zhao J; He T; Wang J; Li B
    Cancer Treat Res Commun; 2021; 27():100377. PubMed ID: 33945921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
    Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Li J; Wang Q; Ge J; Tian Y; Yao W
    Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
    Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
    Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report.
    Wu CH; Su PL; Hsu CW; Chu CY; Lin CC
    Thorac Cancer; 2021 Nov; 12(22):3068-3071. PubMed ID: 34623764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
    Roys A; Chang X; Liu Y; Xu X; Wu Y; Zuo D
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):679-688. PubMed ID: 31256210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
    Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
    Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 31. Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study.
    Seki Y; Yoshida T; Kohno T; Masuda K; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Kuwano K; Ohe Y
    Respir Investig; 2022 Nov; 60(6):852-856. PubMed ID: 36089506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crizotinib inhibition of
    Bebb DG; Agulnik J; Albadine R; Banerji S; Bigras G; Butts C; Couture C; Cutz JC; Desmeules P; Ionescu DN; Leighl NB; Melosky B; Morzycki W; Rashid-Kolvear F; Lab C; Sekhon HS; Smith AC; Stockley TL; Torlakovic E; Xu Z; Tsao MS
    Curr Oncol; 2019 Aug; 26(4):e551-e557. PubMed ID: 31548824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
    Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
    Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
    Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
    Drilon A; Somwar R; Wagner JP; Vellore NA; Eide CA; Zabriskie MS; Arcila ME; Hechtman JF; Wang L; Smith RS; Kris MG; Riely GJ; Druker BJ; O'Hare T; Ladanyi M; Davare MA
    Clin Cancer Res; 2016 May; 22(10):2351-8. PubMed ID: 26673800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
    Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
    J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.
    Jóri B; Vössing C; Pirngruber J; Willing EM; Arndt K; Falk M; Tiemann M; Heukamp LC; Hoffknecht P
    Curr Oncol; 2023 Sep; 30(10):8805-8814. PubMed ID: 37887535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.